Effect of 4 weeks treatment with Acipimox on left ventricular function, work capacity, insulin sensitivity and substrate metabolism in patients with chronic heart failure
- Conditions
- chronic stable heart failureMedDRA version: 9.1Level: LLTClassification code 10008908Term: Chronic heart failure
- Registration Number
- EUCTR2007-002321-74-DK
- Lead Sponsor
- Aarhus University Hospital, Skejby sygehus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Chronic heart failure
Ischemic heart disease
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Age <18 or >85, Recent myocardial infarction (<6 weeks), renal failure, Insulintreated diabetes, Gastric Ulcer, pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To test the the potential and the metabolic consequences of acipimox-treatment in chronic heart failure and the effects on cardiac metabolism;Secondary Objective: ;Primary end point(s): myocardial glucose- protein- and free fatty acid-extraction<br>Global Left ventricular function <br>Forearm (muscular metabolism)<br>
- Secondary Outcome Measures
Name Time Method